VP (Global Head), Business Development & Alliance Mgmt
Description
- Well financed, stable, and profitable commercial-stage pharma ($1.5B sales / $9B mkt cap) with a uniquely attractive company culture
- Newly-created role with direct reports
- Reports to a personable C-level executive that we introduced to this company
- Work across multiple modalities (mAb/bsAb, ADC, I-O, small molecules)
- Full spectrum of BD&L activities (in- & out-licensing, acquisitions, research collaborations, and co-development / co-commercialization industry partnerships)
- Hybrid role – with minimal on-site required. There is flexibility to live in northern or central states within Eastern Time Zone (ET)
Cornerstone Search Group is pleased to partner again with a highly-successful oncology-focused pharmaceutical company that is fast growing and financially healthy ($1.5B in sales and $9B market cap – both of which grew tremendously YoY) and has a positive work environment and renowned culture. With a fast-growing oncology blockbuster and a Phase III candidate also anticipated to be a blockbuster, our client is in a very active phase of building out their pipeline through both in-house research as well as research collaboration, in-licensing, and M&A efforts across multiple modalities (ADC, BsAb, mAb, small molecule). For this newly-created VP, Global Head of Business Development & Alliance Management position, our client is seeking an entrepreneurial and experienced BD&L professional who is passionate and scientifically knowledgeable about oncology, has a proven track record in small or mid-size pharma/biotech BD&L activities, and who values working in close collaboration with high EQ, high integrity professionals in a low bureaucracy, hands-on environment.
Location
This is a hybrid role with office locations in the New York City and Boston metro areas. There is minimal on-site required. Our client prefers candidates located in the Eastern Time Zone and from states within reasonable and convenient travel distance from either of their offices, such as Massachusetts MA, New Jersey NJ, New York NY, Pennsylvania PA, Connecticut CT, Maryland MD, Washington, D.C. DC, Virginia VA, North Carolina NC, Delaware DE, Maine ME, Rhode Island RI, and Ohio OH.
Features
- Newly created role with direct reports
- This is a growing, profitable, stable, and publicly traded company with $1.5Bn+ in revenue and a $9.5Bn market cap that still retains a small company feel with limited layers
- Our client internally discovered a fast-growing oncology blockbuster that has plenty of patent life remaining as well as a Phase III asset that is anticipated to also achieve blockbuster status.
- We have partnered with our client multiple times before, so we know them quite well, including the hiring manager for this position (whom we introduced to this company). The people that we have helped to join this company have been very happy with the culture and impressed with executive management and their peers.
- Hybrid role - minimal on-site required. There is flexibility to live in northern or central states within Eastern Time Zone (ET)
Responsibilities
- You and your team of direct reports will identify, source, and negotiate the full-spectrum of BD&L activities including licensing agreements (in- and out-licensing of assets), research collaborations (with academic institutions and private companies), global partnerships (co-development and co-commercialization), and acquisitions.
- You will lead teams (including your direct reports, cross-functional team members, and partnership representatives) such as “Search & Evaluation” and “Alliance Management” that will conduct the commercial and scientific assessment of BD opportunities, build models to support deal negotiations, negotiate deals and contracts, manage virtual data rooms, etc.
- Develop new relationships with key stakeholders, academic institutions, and future industry partners.
- Maintain relationships with current research collaboration and co-development/co-commercialization industry partners.
- Build out the BD&L and Alliance Management infrastructure.
Qualifications / Requirements
DESIRED SKILLS / EXPERIENCES / EDUCATION / BEHAVIORS:
- Ideally 12+ years of pharmaceutical / biotech industry experience including oncology BD leadership experience (TA lead or department lead) for a clinical stage or small/mid-size commercial stage company.
- Advanced scientific education (PhD, PharmD, MD, MS) is preferred. An MBA or JD is a plus.
- Demonstrated oncology BD&L experience, preferably in 2 or more of the following activities: in-licensing, out-licensing, M&A, research collaborations, co-dev partnership, co-commercial partnership.
- Alliance Management experience is a plus.
- Seeking someone who has the breadth of knowledge and skills necessary for leading BD in a smaller environment, including scientific, regulatory, and IP / legal knowledge as well as negotiation, analytical, leadership, project management, and communication skills.
- Prior direct report experience is a plus.
- Experience working on a global basis is a plus.
- Prior experience in strategy consulting, VC / PE, investment banking, and/or corporate development environments is welcomed.
- Desire and a comfort level with working hands-on and in a fast-paced environment.
- The hiring manager seeks someone with the courage to challenge the status quo and advocate for innovative ideas.
- Leadership indexes on high emotional intelligence coupled with a commitment to a high level of collaboration, integrity, ethical standards.
- Willingness to travel internationally as needed.
Contact
Recently Completed Retained Searches by Cornerstone
REPRESENTATIVE RETAINED SEARCH ASSIGNMENTS:- CEO | specialty pharma start-up
- CEO | regenerative medicine start-up
- US CEO | established European small pharma
- President/US Commercial Head | generics pharma
- CMO | late-stage public biotech
- CMO | mid-size pharma
- CMO | European commercial-stage, oncology-focused public biopharma
- CSO | mid-size global biotech
- CCO | European Commercial-Stage Pharma
- CLO | $2Bn market cap clinical-stage biotech
- SVP, Head of Global Medical Affairs | mid-size oncology company
- SVP, Head of Global Clinical Development | multi-TA mid-size pharma
- SVP, Head of Global Regulatory Affairs | late-stage Israeli biotech
- Global Head, Oncology R&D | mid-size European pharma
- Group VP, Global Commercial Head | API Business Unit | Indian pharma
- VP, Business Development | $1.5Bn global pharma
- VP, Data Science RWE | Top 5 Pharma
- VP, Head of Regulatory Affairs | Boston biotech
- VP, US Head of Regulatory Affairs | Top 20 Pharma
- VP, Head of R&D Operations | Boston biotech
- VP, Head of HEOR (Health Economics & Outcomes Research | Top CNS specialty pharma
- VP, Head of US HEOR & RWE | Top 5 Pharma
- VP, Head of Real-World Evidence | Top 5 pharma
- VP, Head of US HEOR | Top Oncology Pharma
- ED, Head of HEOR | Top West Coast Pharma
- VP, Head of Global Market Access | Top Oncology Specialty Pharma
- VP, Head of US Market Access | High-profile late stage biotech
- VP, Head of US Market Access | West Coast Late-Stage Public Biotech
- VP, Head of Heme/Onc Clinical Research | Public oncology biotech
- VP, Head of Clinical Development | late-stage anti-infectives UK pharma
- VP, Head of Global Drug Safety & PV | Chinese oncology biotech
- ED, Head of Clinical Operations | British VC-backed biotech
- ED, Global Commercial Strategy Franchise Head | Top rare disease Boston pharma
- ED, Head of Global Clinical Pharmacology | Public oncology biotech
- ED, Head of Global HEOR | Large US Pharma
- Head, Patient Advocacy | European commercial-stage rare disease biotech
- Medical Directors (Director/SD/ED levels) in Translational Medicine / Clinical Development / Medical Affairs / Drug Safety: 75+ retained assignments
- HEOR/RWE/Market Access (AD/Director/SD/ED levels): 100+ retained assignments
Cornerstone's Privacy Policy
Cornerstone Search Group considers all inquiries, resume submissions, and any other personal information submitted to us as confidential information. This information will not be shared with any parties outside of Cornerstone Search Group without your prior permission.
Keywords
antibody-drug conjugate bi-specific bispecific TKI solid tumor IO immuno-oncology immunooncology CAR-T cancer